Related Experiment Video

Updated: Jul 19, 2026

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis
09:33

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis

Published on: March 20, 2026

Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy

Victor L J L Thijssen1, Ruben Postel, Ricardo J M G E Brandwijk

  • 1Angiogenesis Laboratory, Research Institute for Growth and Development (GROW), Department of Pathology, University Maastricht, 6202A2 Maastricht, The Netherlands.

Proceedings of the National Academy of Sciences of the United States of America
|October 18, 2006
PubMed

Insights

Galectin-1 (gal-1) acts as a receptor for anginex, a key regulator of tumor angiogenesis. Inhibiting gal-1 significantly impairs tumor growth and vascularization, highlighting its therapeutic potential.

Area of Science:

  • Oncology
  • Molecular Biology
  • Vascular Biology

Background:

  • Tumor angiogenesis is essential for tumor growth and metastasis.
  • Angiogenesis inhibitors are a promising cancer therapy strategy.
  • The specific molecular mechanisms regulating tumor angiogenesis are not fully understood.

Purpose of the Study:

  • To investigate the role of galectin-1 (gal-1) in tumor angiogenesis.
  • To determine if gal-1 is a receptor for the angiogenesis inhibitor anginex.
  • To evaluate gal-1 as a potential therapeutic target for anti-angiogenesis cancer therapy.

Main Methods:

  • Galectin-1 (gal-1) expression analysis in tumor endothelial cells.
  • Gal-1 knockdown in cultured endothelial cells to assess proliferation and migration.
  • Zebrafish model to study the effects of gal-1 knockdown on angiogenesis.
  • Tumor growth studies in gal-1-null mice treated with anginex.

Main Results:

  • Galectin-1 (gal-1) is overexpressed in endothelial cells of human tumors.
  • Gal-1 knockdown inhibits endothelial cell proliferation and migration.
  • Gal-1 knockdown in zebrafish impairs vascular development.
  • Tumor growth is significantly reduced in gal-1-null mice due to impaired angiogenesis.
  • Tumor growth in gal-1-null mice is unresponsive to anginex treatment.

Conclusions:

  • Galectin-1 (gal-1) is a crucial regulator of tumor angiogenesis.
  • Gal-1 functions as a receptor for the angiogenesis inhibitor anginex.
  • Gal-1 represents a novel therapeutic target for anti-angiogenesis cancer strategies.

More Related Videos

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells09:03

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Published on: November 23, 2014

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Activation of Integrins01:15

Activation of Integrins

Integrins bind ligands and transmit information from outside the cell to inside or vice-versa through an "outside-in signaling" or "inside-out signaling."
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding events provide an effective stimulus.
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...